How Medicines for Treating Obesity Have Changed Over Time

Current injectable medications like semaglutide and tirzepatide are associated with a mean weight loss of 15%-20% over approximately 12-18 months.

• Many obesity medications have been withdrawn from the market due to safety concerns in the past.
• Advancements in understanding appetite and energy balance have led to the development of safer and more effective medications.
• The current generation of obesity drugs provides significant cardiometabolic benefits, including reduced cardiovascular and kidney risks.
• These medications also improve blood sugar levels, blood pressure, lipid profiles, and liver health.
• As new treatments are developed, obesity medications may become essential in managing cardiometabolic diseases.

Simplified